AI assistant
IMPEDIMED LIMITED — AGM Information 2023
Oct 11, 2023
65135_rns_2023-10-11_60304886-b6db-4ec6-bd03-9edd871ebc84.pdf
AGM Information
Open in viewerOpens in your device viewer
==> picture [132 x 24] intentionally omitted <==
12 October 2023
ASX ANNOUNCEMENT
Date of 2023 Annual General Meeting
ImpediMed Limited (ASX.IPD) ( ImpediMed or Company ) advises that its 2023 Annual General Meeting will be held on Thursday, 30 November 2023 commencing at 11.00am AEDT.
Further details will be provided in the Notice of Meeting which will be released to the ASX at the end of October 2023.
ImpediMed further advises that nominations from persons seeking to be considered for election as a director of the Company are required to be received at the registered office of the Company by 5.00pm AEDT on 19 October 2023.
Approved for release by the Board of the Company.
Contact Details
Investor Relations Contact:
Hannah Howlett WE Communications
T: +61 450 648 064
About ImpediMed
Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO[®] Digital Health Platform, which is FDAcleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.
In March 2023, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines[®] ) for Survivorship were updated and reference bioimpedance spectroscopy as the recommended objective tool to screen atrisk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex[®] , ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancerrelated lymphoedema market present an opportunity for continued strong growth through ImpediMed’s SaaS subscription-based business.
For more information, visit www.impedimed.com.
==> picture [132 x 24] intentionally omitted <==
Forward-Looking Statements
This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions and expectations and on information currently available to management.
All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.
Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.